MedTrace Logo

A Study to Evaluate HB0034 in Healthy Adult Participants

NCT05064345 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-09-14

No results posted yet for this study

Summary

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose.

Conditions

  • Healthy

Interventions

DRUG

HB0034

Recombinant Humanized Anti-IL-36R Monoclonal antibody

DRUG

Placebo

Palcebo

Sponsors & Collaborators

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Christian Schwabe · NZCR OpCo limited AKL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-03
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05064345 on ClinicalTrials.gov